Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...

Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...

Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...